Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

GCC Ophthalmic Drugs Devices Market

ID: MRFR/Pharma/51783-HCR
200 Pages
Vikita Thakur
Last Updated: March 28, 2026

GCC Ophthalmic Drugs and Devices Market Research Report By Product (Drugs, Devices) and By Treatment (Eye Infections, Allergic Conjunctivitis, Dry Eyes Syndrome, Red Eyes, Inflammation, Others) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

GCC Ophthalmic Drugs Devices Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Glaucoma Treatment
  50.     4.1.2 Anti-Inflammatory
  51.     4.1.3 Infection Control
  52.     4.1.4 Dry Eye Treatment
  53.     4.1.5 Surgical Procedures
  54.   4.2 Healthcare, BY Device Type (USD Billion)
  55.     4.2.1 Intraocular Lens
  56.     4.2.2 Surgical Instruments
  57.     4.2.3 Diagnostic Equipment
  58.     4.2.4 Contact Lenses
  59.     4.2.5 Ocular Drug Delivery Systems
  60.   4.3 Healthcare, BY Formulation Type (USD Billion)
  61.     4.3.1 Topical Solutions
  62.     4.3.2 Injectable Solutions
  63.     4.3.3 Ocular Implants
  64.     4.3.4 Sustained Release Formulations
  65.     4.3.5 Ophthalmic Gels
  66.   4.4 Healthcare, BY End User (USD Billion)
  67.     4.4.1 Hospitals
  68.     4.4.2 Clinics
  69.     4.4.3 Home Care Settings
  70.     4.4.4 Research Institutions
  71.     4.4.5 Pharmacies
  72. 5 SECTION V: COMPETITIVE ANALYSIS
  73.   5.1 Competitive Landscape
  74.     5.1.1 Overview
  75.     5.1.2 Competitive Analysis
  76.     5.1.3 Market share Analysis
  77.     5.1.4 Major Growth Strategy in the Healthcare
  78.     5.1.5 Competitive Benchmarking
  79.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  80.     5.1.7 Key developments and growth strategies
  81.       5.1.7.1 New Product Launch/Service Deployment
  82.       5.1.7.2 Merger & Acquisitions
  83.       5.1.7.3 Joint Ventures
  84.     5.1.8 Major Players Financial Matrix
  85.       5.1.8.1 Sales and Operating Income
  86.       5.1.8.2 Major Players R&D Expenditure. 2023
  87.   5.2 Company Profiles
  88.     5.2.1 Alcon (CH)
  89.       5.2.1.1 Financial Overview
  90.       5.2.1.2 Products Offered
  91.       5.2.1.3 Key Developments
  92.       5.2.1.4 SWOT Analysis
  93.       5.2.1.5 Key Strategies
  94.     5.2.2 Bausch + Lomb (US)
  95.       5.2.2.1 Financial Overview
  96.       5.2.2.2 Products Offered
  97.       5.2.2.3 Key Developments
  98.       5.2.2.4 SWOT Analysis
  99.       5.2.2.5 Key Strategies
  100.     5.2.3 Novartis (CH)
  101.       5.2.3.1 Financial Overview
  102.       5.2.3.2 Products Offered
  103.       5.2.3.3 Key Developments
  104.       5.2.3.4 SWOT Analysis
  105.       5.2.3.5 Key Strategies
  106.     5.2.4 Johnson & Johnson (US)
  107.       5.2.4.1 Financial Overview
  108.       5.2.4.2 Products Offered
  109.       5.2.4.3 Key Developments
  110.       5.2.4.4 SWOT Analysis
  111.       5.2.4.5 Key Strategies
  112.     5.2.5 AbbVie (US)
  113.       5.2.5.1 Financial Overview
  114.       5.2.5.2 Products Offered
  115.       5.2.5.3 Key Developments
  116.       5.2.5.4 SWOT Analysis
  117.       5.2.5.5 Key Strategies
  118.     5.2.6 Santen Pharmaceutical (JP)
  119.       5.2.6.1 Financial Overview
  120.       5.2.6.2 Products Offered
  121.       5.2.6.3 Key Developments
  122.       5.2.6.4 SWOT Analysis
  123.       5.2.6.5 Key Strategies
  124.     5.2.7 Hoya Corporation (JP)
  125.       5.2.7.1 Financial Overview
  126.       5.2.7.2 Products Offered
  127.       5.2.7.3 Key Developments
  128.       5.2.7.4 SWOT Analysis
  129.       5.2.7.5 Key Strategies
  130.     5.2.8 Carl Zeiss AG (DE)
  131.       5.2.8.1 Financial Overview
  132.       5.2.8.2 Products Offered
  133.       5.2.8.3 Key Developments
  134.       5.2.8.4 SWOT Analysis
  135.       5.2.8.5 Key Strategies
  136.     5.2.9 Merck Group (DE)
  137.       5.2.9.1 Financial Overview
  138.       5.2.9.2 Products Offered
  139.       5.2.9.3 Key Developments
  140.       5.2.9.4 SWOT Analysis
  141.       5.2.9.5 Key Strategies
  142.   5.3 Appendix
  143.     5.3.1 References
  144.     5.3.2 Related Reports
  145. 6 LIST OF FIGURES
  146.   6.1 MARKET SYNOPSIS
  147.   6.2 GCC MARKET ANALYSIS BY APPLICATION
  148.   6.3 GCC MARKET ANALYSIS BY DEVICE TYPE
  149.   6.4 GCC MARKET ANALYSIS BY FORMULATION TYPE
  150.   6.5 GCC MARKET ANALYSIS BY END USER
  151.   6.6 KEY BUYING CRITERIA OF HEALTHCARE
  152.   6.7 RESEARCH PROCESS OF MRFR
  153.   6.8 DRO ANALYSIS OF HEALTHCARE
  154.   6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  155.   6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  156.   6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
  157.   6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  158.   6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  159.   6.14 HEALTHCARE, BY DEVICE TYPE, 2024 (% SHARE)
  160.   6.15 HEALTHCARE, BY DEVICE TYPE, 2024 TO 2035 (USD Billion)
  161.   6.16 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
  162.   6.17 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
  163.   6.18 HEALTHCARE, BY END USER, 2024 (% SHARE)
  164.   6.19 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
  165.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  166. 7 LIST OF TABLES
  167.   7.1 LIST OF ASSUMPTIONS
  168.     7.1.1
  169.   7.2 GCC MARKET SIZE ESTIMATES; FORECAST
  170.     7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  171.     7.2.2 BY DEVICE TYPE, 2026-2035 (USD Billion)
  172.     7.2.3 BY FORMULATION TYPE, 2026-2035 (USD Billion)
  173.     7.2.4 BY END USER, 2026-2035 (USD Billion)
  174.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  175.     7.3.1
  176.   7.4 ACQUISITION/PARTNERSHIP
  177.     7.4.1

GCC Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

  • Glaucoma Treatment
  • Anti-Inflammatory
  • Infection Control
  • Dry Eye Treatment
  • Surgical Procedures

Healthcare By Device Type (USD Billion, 2026-2035)

  • Intraocular Lens
  • Surgical Instruments
  • Diagnostic Equipment
  • Contact Lenses
  • Ocular Drug Delivery Systems

Healthcare By Formulation Type (USD Billion, 2026-2035)

  • Topical Solutions
  • Injectable Solutions
  • Ocular Implants
  • Sustained Release Formulations
  • Ophthalmic Gels

Healthcare By End User (USD Billion, 2026-2035)

  • Hospitals
  • Clinics
  • Home Care Settings
  • Research Institutions
  • Pharmacies

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓